OBJECTIVE: Gut microbiota represent a potential novel target for future prediabetes and type 2 diabetes therapies. In that respect, niacin has been shown to beneficially affect the host-microbiome interaction in rodent models. RESEARCH DESIGN AND METHODS: We characterized more than 500 human subjects with different metabolic phenotypes regarding their niacin (nicotinic acid [NA] and nicotinamide [NAM]) status and their gut microbiome. In addition, NA and NAM delayed-release microcapsules were engineered and examined in vitro and in vivo in two human intervention studies (bioavailability study and proof-of-concept/safety study). RESULTS: We found a reduced α-diversity and Bacteroidetes abundance in the microbiome of obese human subjects associated with a low dietary niacin intake. We therefore developed delayed-release microcapsules targeting the ileocolonic region to deliver increasing amounts of NA and NAM to the microbiome while preventing systemic resorption to avoid negative side effects (e.g., facial flushing). In vitro studies on these delayed-release microcapsules revealed stable conditions at pH 1.4, 4.5, and 6.8, followed by release of the compounds at pH 7.4, simulating the ileocolonic region. In humans in vivo, gut-targeted delayed-release NA but not NAM produced a significant increase in the abundance of Bacteroidetes. In the absence of systemic side effects, these favorable microbiome changes induced by microencapsulated delayed-release NA were associated with an improvement of biomarkers for systemic insulin sensitivity and metabolic inflammation. CONCLUSION: Targeted microbiome intervention by delayed-release NA might represent a future therapeutic option for prediabetes and type 2 diabetes.
OBJECTIVE: Gut microbiota represent a potential novel target for future prediabetes and type 2 diabetes therapies. In that respect, niacin has been shown to beneficially affect the host-microbiome interaction in rodent models. RESEARCH DESIGN AND METHODS: We characterized more than 500 human subjects with different metabolic phenotypes regarding their niacin (nicotinic acid [NA] and nicotinamide [NAM]) status and their gut microbiome. In addition, NA and NAM delayed-release microcapsules were engineered and examined in vitro and in vivo in two human intervention studies (bioavailability study and proof-of-concept/safety study). RESULTS: We found a reduced α-diversity and Bacteroidetes abundance in the microbiome of obesehuman subjects associated with a low dietary niacin intake. We therefore developed delayed-release microcapsules targeting the ileocolonic region to deliver increasing amounts of NA and NAM to the microbiome while preventing systemic resorption to avoid negative side effects (e.g., facial flushing). In vitro studies on these delayed-release microcapsules revealed stable conditions at pH 1.4, 4.5, and 6.8, followed by release of the compounds at pH 7.4, simulating the ileocolonic region. In humans in vivo, gut-targeted delayed-release NA but not NAM produced a significant increase in the abundance of Bacteroidetes. In the absence of systemic side effects, these favorable microbiome changes induced by microencapsulated delayed-release NA were associated with an improvement of biomarkers for systemic insulin sensitivity and metabolic inflammation. CONCLUSION: Targeted microbiome intervention by delayed-release NA might represent a future therapeutic option for prediabetes and type 2 diabetes.
Authors: Heather M Guetterman; Samantha L Huey; Rob Knight; Allison M Fox; Saurabh Mehta; Julia L Finkelstein Journal: Adv Nutr Date: 2021-10-06 Impact factor: 8.701
Authors: Corinna Geisler; Kristina Schlicht; Carina Knappe; Nathalie Rohmann; Katharina Hartmann; Kathrin Türk; Ute Settgast; Dominik M Schulte; Tobias Demetrowitsch; Julia Jensen-Kroll; Alina Pisarevskaja; Fynn Brix; Bärbel Gruber; Gerald Rimbach; Frank Döring; Philip Rosenstiel; Andre Franke; Stefan Schreiber; Christian H C A Henning; Wolfgang Lieb; Ute Nöthlings; Karin Schwarz; Matthias Laudes Journal: Eur J Epidemiol Date: 2022-10-16 Impact factor: 12.434
Authors: Mehmet Kanbay; Emine M Onal; Baris Afsar; Tuncay Dagel; Aslihan Yerlikaya; Adrian Covic; Nosratola D Vaziri Journal: Int Urol Nephrol Date: 2018-05-04 Impact factor: 2.370
Authors: Van T Pham; Sophie Fehlbaum; Nicole Seifert; Nathalie Richard; Maaike J Bruins; Wilbert Sybesma; Ateequr Rehman; Robert E Steinert Journal: Gut Microbes Date: 2021 Jan-Dec
Authors: Van T Pham; Marta Calatayud; Chloë Rotsaert; Nicole Seifert; Nathalie Richard; Pieter Van den Abbeele; Massimo Marzorati; Robert E Steinert Journal: Nutrients Date: 2021-03-29 Impact factor: 5.717